Graves’ disease and Graves Ophthalmopathy
Conditions
Interventions
1:Antithyroid drugs
2:methylprednisolone pulse therapy
Sponsors
First Affiliated Hospital of Xi'an Jiaotong University Health Science Center
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Graves' disease: newly diagnosed (duration < 2 months) Graves Ophthalmopathy: 1. Moderately to severely active TAO; 2. CAS score is equal or more than 4; 3. The grade of NOSPECS is equal or more than 40; 4. The duration of Graves' Ophthalmopathy is less than 3 months, and the disease becomes serious recently, including the aggravation of some already existing symptoms or signs and/or the emergence of new-onset symptoms or signs; 5. There is no need to do the operation of orbital decompression,after the ophthalmologist' assessment; 6. All of the patients were informed of the possible short- and long-term sideeffects of high-dose IVMP therapy, and they all voluntarily joined this study with informed consents.
Exclusion criteria
Exclusion criteria: Graves' disease: 1. Patients who are allergic to anti-thyroid drugs; 2. Patients who is suffering from one or two complications, including an active peptic ulcer, a recent gastrointestinal surgery, serious diabetes, hypertension, hyperlipidemia, glaucoma, osteoporosis, heart disease, cardiac failure, hepatic impairment, impaired renal function and urolithiasis; 3. Pregnant and lactating women; 4. Combined with someother autoimmune diseases. Graves Ophthalmopathy: 1. Patients who were infected by fungus,mycobacterium tuberculosis, hepatitis virus and/or any other uncontrolled bacterium,virus and fungus; 2. Patients who are allergic to methylprednisolone; 3. Patients who have a history of serious mental disease and/or epilepsy; 4. Patients who is suffering from one or two complications, including an active peptic ulcer, a recent gastrointestinal surgery, serious diabetes, hypertension, hyperlipidemia, glaucoma, osteoporosis, heart disease, cardiac failure, hepatic impairment, impaired renal function and urolithiasis; 5. Pregnant and lactating women; 6. Combined with someother autoimmune diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thyroid Function;TCR repertoire; | — |
Countries
China
Contacts
Public ContactBingyin Shi
Outcome results
None listed